唐氏综合征患者牛皮的生物和小分子疗法:两个病例和系统审查
Michal Moshkovich1, Jonah W Perlmutter1, Ronald Vender2
1Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
SAGE open medical case reports
|July 28, 2025
概括
唐氏综合征 (DS) 患者患上牛皮的风险更高. 针对IL-17和IL-23通路的生物药物显示出治疗多发性病患者的牛皮的前景,与甲醇相反.
科学领域:
- 皮肤病学 皮肤病学
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 唐氏综合征 (DS) 或三症21与皮肤疾病的患病率增加有关.
- 牛皮会影响多达8%的DS患者,造成独特的管理挑战.
- 免疫抑制疗法可能会在DS患者中带来理论上的感染风险.
研究的目的:
- 总结牛皮的特征和DS患者的治疗结果.
- 介绍两例患有牛皮的DS患者及其治疗反应的不同情况.
- 对DS和牛皮的现有文献进行系统审查.
主要方法:
- 关于两名患有牛皮的DS患者的病例报告.
- 按照PRISMA指南进行系统的文献审查.
- 分析了10项研究,其中包括37名患有牛皮的DS患者.
主要成果:
- 在案例研究中观察到对阿西特雷丁和塞库金纽马布等治疗的可变反应.
- 甲托雷克萨特是多发性牛皮患者中最常见的失败疗法.
- 针对IL-17和IL-23通路的生物药物表现出最高的完全解决率.
结论:
- 牛皮管理在DS需要个性化,路径特定的策略.
- Th1/Th17驱动的炎症与DS相关的牛皮有关.
- IL-17和IL-23抑制剂对唐氏综合征的牛皮有效.
相关概念视频
iPS Cell Differentiation
2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
EPS and iPS Cells in Disease Research
2.9K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235
Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193


